How Mounjaro interacts with your hormones

Which hormones does Mounjaro actually target?

The short answer is two gut hormones: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are incretins — hormones released by cells in your gut wall within minutes of eating, whose job is to tell the pancreas to release insulin and tell the brain that food has arrived. In most people with obesity, this signalling becomes blunted over time, so the brain's fullness response is slower and weaker than it should be.

Tirzepatide's molecules are synthetic analogues designed to dock with the receptors for both hormones. Because the drug binds those receptors for a full week rather than the few minutes natural incretins manage, the appetite-dampening signal is sustained rather than fleeting. That sustained signal is what separates tirzepatide from earlier GLP-1-only medicines and is the mechanistic reason the SURMOUNT-1 trial (published in the New England Journal of Medicine) reported an average body-weight reduction of around 20–21% at the highest dose over 72 weeks. Being a dual-agonist is not a marketing detail; it is a meaningful pharmacological distinction.

If you want to go deeper on whether tirzepatide should be described as a hormone itself, our page on whether Mounjaro is a hormone unpacks that question specifically.

Does Mounjaro affect other hormones beyond GIP and GLP-1?

This is one of the questions our prescribers hear regularly, and it deserves a careful answer. Mounjaro does not directly target sex hormones (oestrogen, progesterone, testosterone) nor does it act on thyroid hormones in a way that is part of its licensed mechanism. The NHS notes that tirzepatide is not linked to direct suppression of these hormones as a pharmacological effect.

What does happen is indirect. Adipose tissue (body fat) is itself hormonally active: it produces oestrogen, leptin, and inflammatory signals that feed back into wider endocrine function. As body weight falls on tirzepatide, those secondary hormonal patterns can shift. People with polycystic ovary syndrome (PCOS), for example, often report changes in cycle regularity as weight decreases — not because Mounjaro targets their reproductive hormones, but because reduced fat mass can improve insulin sensitivity and reduce the excess androgen production associated with the condition.

For a fuller look at how tirzepatide interacts with female hormonal health specifically, the dedicated page on tirzepatide and female hormones covers that ground in detail. Our page on tirzepatide and hormone balance addresses the broader picture.

What does this mean for your appetite and energy day to day?

The practical experience of the hormonal mechanism is a quieter relationship with hunger. Most people on tirzepatide describe food as less compelling rather than repulsive, the background noise of appetite simply turns down. Gastric emptying slows, so meals feel satisfying on smaller portions, and blood sugar rises more gradually after eating, which smooths out the energy spikes and crashes that drive snacking.

These effects build gradually as the dose is titrated up, which is why treatment begins at 2.5mg, a dose calibrated to let your system adjust, not to maximise the hormonal signal immediately. The titration schedule is managed by your prescriber. The NHS medicines page on tirzepatide describes the common side effects that arise during this adjustment, most of which are gastrointestinal: nausea, looser stools, indigestion. They typically ease within a couple of weeks of each dose change.

One practical note on timing: if you are planning a holiday, starting treatment the week before travelling adds a layer of complexity that your prescriber can help you think through. Orders placed before midday Monday to Friday are reviewed the same working day by a named clinician at our pharmacy, so there is usually no need to rush.

Are there any hormonal considerations before starting Mounjaro?

A few are worth knowing before your consultation. If you take an oral contraceptive pill, MHRA guidance advises adding a non-oral method of contraception for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, because the slower gastric emptying that forms part of tirzepatide's mechanism may reduce pill absorption. How Mounjaro affects other medications (including the pill) is covered in more detail in a dedicated page.

People with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not take tirzepatide; the prescriber will screen for this during your consultation. Pregnancy and breastfeeding are absolute contraindications, and women who are trying to conceive are advised not to use Mounjaro. Those considerations aside, no specific hormonal pre-testing is routinely required before starting, your prescriber assesses your full medical picture during the consultation.

If cost is something you are weighing up, the treatment and consultation page explains what is included in a single transparent price. And if you are curious whether tirzepatide might suit your situation, our Mounjaro overview covers the wider picture before you reach the consultation stage.